Dr Sanjay Patel, Group Leader of the Cell Therapeutic Group

Meet the team

Dr Sanjay Patel has led the HRI’s Cell Therapeutic Group since 2012. The Cell Therapeutic Group is a close knit team of researchers composed of two postdoctoral fellows, three PhD students and a research assistant.

Sanjay began his scientific career by completing a Bachelors of Medicine and Surgery, for which he received first class honours. He underwent basic training at the Royal Prince Alfred Hospital and Concord Repatriation Hospital, before returning to RPAH to complete his cardiology training in 2005. 

Sanjay began his association with the HRI with the commencement of his PhD studies. He worked with Professors David Celermajer, Philip Barter, and Kerry-Ann Rye to investigate the biology of high density lipoproteins. During this time he maintained ties with the RPAH as Cardiology Research Fellow and later as Interventional Cardiology Fellow.  

In 2009, Sanjay began a clinical interventional cardiology and postdoctoral fellowship in stem cell biology at Stanford University School of Medicine under Professor John Cooke. Professor Cooke is another pivotal figure for Sanjay, a vascular biologist of world acclaim who has inspired Sanjay’s own career. 

Sanjay is enthusiastic about his future with the HRI.

“I have been with the HRI since starting my PhD studies and the supportive research environment has enabled me to now head a growing research team of my own,” explained Sanjay. “A particular strength of the HRI is its strong collaborative links,”

Sanjay preserves a strong collaborative relationship with Professor Celermajer, the Clinical Director of the HRI, whom he credits with teaching him the inherent rewards in translating high quality research into a clinical setting. Sanjay’s diverse skill set combines expertise in fundamental vascular biology along with interventional cardiology, uniquely placing him to lead research from the laboratory bench to the patient bedside. 

Sanjay aims to establish a comprehensive research program at the HRI, tasked with suppressing inflammation in the setting of atherosclerosis.

“In the future, I see our basic science and translational research moving forward into world class multicentre clinical trials,” Sanjay explained. “Importantly, our research has the potential to dramatically improve health outcomes and alleviate the burgeoning costs associated with heart disease.”

Drawn to the honesty, rigour and precision of scientific research, Sanjay enjoys applying this same discipline to his clinical work. He appreciates the variety research gives to his working life, and the opportunity to apply fundamental science directly to the patients he treats. 

Sanjay was born into a strong medical lineage. Having a cardiologist father and general practitioner mother, Sanjay and his sister showed an early aptitude for science at school. 

Naturally energetic and driven, Sanjay makes an extra effort to switch off and unwind. He spends his free time running, cycling and enjoying the company of his young family.


Related news

Scientific minds coming together

HRI researchers Dr Mary Kavurma, Associate Professor Simone Schoenwaelder, Dr Amelia Tomkins and Bradley Tucker attended the ANZMS and AVBS Conference 2017 to share and discuss the latest research in the field.
Read more

HRI shows drug suppresses heart vessel inflammation

In a world-first discovery, scientists at The Heart Research Institute (HRI) and collaborators have shown the anti-inflammatory drug colchicine dramatically reduces local cardiac inflammation when used shortly before cardiac catheterisation. 

Read more

Drug Protects Heart Patients from Attacks

Heart attack survivors could live longer, healthier lives if given an arthritis drug found to dramatically reduce heart inflammation, world-first research shows. The study has revealed that an anti-inflammatory medication used to treat gout can also improve heart health in people who have suffered a heart attack or other major heart event.
Read more